Access to second-line drug susceptibility testing results among patients with Rifampicin resistant tuberculosis

The study examines access after introduction of the Hain ® Line Probe Assay in Southern provinces, Zimbabwe

From:
Department for International Development
Published
9 February 2019
Country:
Zimbabwe
Document Type:
Journal Article
Theme:
Health
Authors:
Timire, C, Sandy, C, Kumar, A.M.V., Ngwenya, M, Murwira, B, Takarinda, K.C. and Harries, A.D.

Abstract

This study aims to determine the proportion of rifampicin-resistant tuberculosis (RR-TB) patients who accessed second-line drug susceptibility testing (SL-DST) results following introduction of the Hain technology in southern provinces, Zimbabwe.

This research was supported by the UK Department for International Development’s Operational Research Capacity Building Programme led by the International Union Against TB and Lung Disease (The Union)

Citation

Timire C, Sandy C, Kumar AMV, Ngwenya M, Murwira B, Takarinda KC, Harries AD. Access to second-line drug susceptibility testing results among patients with Rifampicin resistant tuberculosis after introduction of the Hain ® Line Probe Assay in Southern provinces, Zimbabwe. International Journal of Infectious Diseases. 2019;81:236–43.

Access to second-line drug susceptibility testing results among patients with Rifampicin resistant tuberculosis after introduction of the Hain ® Line Probe Assay in Southern provinces, Zimbabwe

Updates to this page

Published 9 February 2019
Contents